OCTA and Polypoidal Choroidal Vasculopathy (NCT04714242) | Clinical Trial Compass
CompletedNot Applicable
OCTA and Polypoidal Choroidal Vasculopathy
Italy60 participantsStarted 2019-01-15
Plain-language summary
To investigate the structural and vascular features of choroid in patients affected by PCV after Ranibizumab intravitreal injection.
Who can participate
Age range60 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* age older than 60 years
* diagnosis of polypoidal choroidal vasculopathy
* absence of previous ocular surgery, congenital eye disease, high myopia (\>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases.
* absence of significant lens opacities, low-quality OCT-A images.
Exclusion Criteria:
* age older than 80 years
* absence of diagnosis of polypoidal choroidal vasculopathy
* presence of previous ocular surgery, congenital eye disease, high myopia (\>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases.
* presence of significant lens opacities, low-quality OCT-A images.
What they're measuring
1
Study of vascular features of choroid in polypoidal choroidal vasculopathy after intravitreal injections of Ranibizumab